Skip to main content
Premium Trial:

Request an Annual Quote

Telo Genomics, Emery Pharma Ink Collaboration Agreement

NEW YORK – Telo Genomics, a biotech company developing telomere-based oncology testing, announced Wednesday that it has formed a collaboration agreement with contract research organization Emery Pharma. The collaboration will enable the firms to offer complementary cellular and molecular bioanalytical solutions for clinical research and development initiatives to their respective clients, according to a statement.

Financial terms of the agreement were not disclosed.

Telo Genomics' TeloView platform utilizes the 3D features of telomeres as structural biomarkers of genomic instability at the single cell level. The technology is applicable to precision medicine liquid biopsy, the firms said.

Emery, meanwhile, offers biologic drug development and analytical characterization, including intact mass analysis, peptide mapping, and glycan analysis as well as analyses of host cell proteins, post-translational modifications, and immunogenicity and general R&D and cGMP/GLP support.

The memorandum of understanding provides a framework to validate the complementary utility of both platforms, the firms said.

"Aligning our platforms provides powerful capabilities with potential to address challenging biotechnology needs for pharma and diagnostics industries," Emery CEO Ron Najafi said in a statement.

Telo Genomics announced a collaboration with Mayo Clinic in 2019 related to clinical studies of telomere analytics as a prognostic for multiple myeloma, and in 2021, the Toronto-based firm raised C$2.1 million (US$1.7 million) in a private placement. Its laboratory in Toronto was accredited by the College of American Pathologists in April.